The U.S. Food and Drug Administration (FDA) has approved Protega Pharmaceuticals Inc.’s ROXYBOND (oxycodone hydrochloride) immediate-release (IR) CII 10 mg tablet for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate.   According to the company, ROXYBOND is the first and only FDA-approved abuse-deterrent IR 10 mg oxycodone formulation that is expected to reduce abuse by intranasal and intravenous routes.   ROXYBOND is form...